Breast carcinoma with amplified HER2: a gene expression signature specific for trastuzumab resistance and poor prognosis

[1]  Pan Du,et al.  lumi: a pipeline for processing Illumina microarray , 2008, Bioinform..

[2]  M. Pegram.  Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways? , 2008, Clinical breast cancer.

[3]  G. Mills,et al.  Preclinical Testing of Clinically Applicable Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency , 2007, Clinical Cancer Research.

[4]  S. Hunt,et al.  Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[6]  N. Brünner,et al.  Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. , 2007, Clinical chemistry.

[7]  E. Winer,et al.  Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer , 2007, Clinical Cancer Research.

[8]  Thomas J. Smith,et al.  Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Jorma Isola,et al.  Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.

[10]  R. Nahta,et al.  Herceptin: mechanisms of action and resistance. , 2006, Cancer letters.

[11]  D. Hicklin,et al.  Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts , 2006, Clinical Cancer Research.

[12]  Ryuji Kobayashi,et al.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.

[13]  Greg Yothers,et al.  Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[15]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[16]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[18]  S. Batra,et al.  Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy , 2004, British Journal of Cancer.

[19]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[20]  Naoto T. Ueno,et al.  P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells , 2004, Cancer Research.

[21]  D. Slamon,et al.  Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. , 2004, Journal of the National Cancer Institute.

[22]  L. Goldstein,et al.  HER-2 testing in breast cancer using parallel tissue-based methods. , 2004, JAMA.

[23]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[24]  M. Owens,et al.  HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. , 2004, Clinical breast cancer.

[25]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[26]  C. A. Carraway,et al.  Muc4/Sialomucin Complex in the Mammary Gland and Breast Cancer , 2001, Journal of Mammary Gland Biology and Neoplasia.

[27]  M. Piccart-Gebhart,et al.  Node positive breast cancer , 2003 .

[28]  M. Pollak,et al.  Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[29]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[30]  Chi-Hung Lin,et al.  Resistance to tamoxifen‐induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer , 2002, International journal of cancer.

[31]  Y. Lu,et al.  Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). , 2001, Journal of the National Cancer Institute.

[32]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[34]  Louis M Weiner,et al.  New approaches to antibody therapy , 2000, Oncogene.

[35]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[36]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Y. Yarden,et al.  Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.

[38]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[39]  E. Robecchi.  [Pathology of the breast]. , 1954, Minerva ginecologica.